WHAT IS CLAIMED IS:

1. A long-acting injectable composition for the treatment or prevention of a parasitic infection or infestation in a non-human animal comprising:

a) an effective amount of at least one parasiticidal isoxazoline active agent, which is a compound of formula (Ic):



(Ic)

or a pharmaceutically acceptable salt thereof:

wherein

X^1, X^2 and X^2 are each independently H, halogen, C_1-C_3alkyl or C_1-C_3haloalkyl;

b) at least one pharmaceutically acceptable polymer which is a liquid PEG, and/or a neutral oil that is selected from triglycerides of fractionated plant fatty acids with chain lengths of C_8 to C_{10};

c) optionally, at least one co-solvent;

d) optionally, an antioxidant; and

e) optionally at least one pharmaceutically acceptable additive, excipient or mixtures thereof

wherein no other pharmaceutically acceptable polymers are present.

2. The long-acting injectable composition according to claim 1, wherein the isoxazoline active agent is enriched in an enantiomer.

3. The long-acting injectable composition according to claim 2, wherein the isoxazoline active agent is a compound of formula (*S*)-Ic:



(*S*)-Ic

wherein X^1, X^2 and X^3 are independently chloro, fluoro or CF_3;

or a pharmaceutically acceptable salt thereof.

4. The long-acting injectable composition according to any one of claims 1 to 3, wherein;

X^1 is Cl; X^2 is F; and X^3 is $–CF_3$.

5. The long-acting injectable composition according to any one of claims 1 to 4, wherein the liquid PEG is PEG 200, PEG 300 or PEG 400, or a mixture thereof.

6. The long-acting injectable composition according to any one of claims 1 to 5, wherein the composition comprises a co-solvent, and wherein the co-solvent is ethanol, isopropanol or benzyl alcohol, or a mixture thereof.

7. The long-acting composition according to any one of claims 1 to 6, which further comprises an effective amount of at least one additional active agent.

8. The long-acting composition according to claim 7, wherein the additional pharmaceutically active agent is a macrocyclic lactone, a neonicotinoid active agent, a 1-N-arylpyrazole active agent, a cyclic depsipeptide, a benzimidazole, an imidazothiazole, a tetrahydropyrimidine active agent, an organophosphate active agent, levamisole, a paraherquamide active agent, a marcfortine active agent, praziquantel, closantel, pyrantel, morantel, clorsulon, a spinosyn active agent, a spinosoid active agent, an amino acetonitrile active agent, an aryloazol-2-yl cyanoethyl active agent or an insect growth regulator.

9. The long-acting composition according to claim 8, wherein the macrocyclic lactone is abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, ML-1,694,554, milbemectin, milbemycin D, moxidectin or nemadectin.

10. Use of a long-acting injectable composition according to claim 1 in the manufacture of medicament for treating or preventing parasites in an animal in need thereof, wherein the parasites are treated or prevented for about 3 to 6 months.

11. The use according to claim 10 wherein the animal is a dog, a cat, an ovine or a bovine.

12. The use according to claim 10, wherein the parasites are treated or prevented for about 5 to 6 months.

13. The use according to claim 10 wherein the parasites are fleas and/or ticks.

14. A pesticidal and parasiticidal isoxazoline compound of formula (Ie):



(Ie)

or a pharmaceutically or agriculturally acceptable salt thereof.

15. A pesticidal and parasiticidal isoxazoline compound of formula *(S)*-Ie:



(S)-Ie

or a pharmaceutically or agriculturally acceptable salt thereof.

16. A veterinary parasiticidal composition comprising an effective amount of the compound of formula (Ie) as defined in claim 14, or a compound of formula *(S)*-Ie as defined in claim 15, in combination with a pharmaceutically acceptable carrier.

17. The compound of formula (Ie) as defined in claim 14 or the compound of formula (S)-Ie as defined in claim 15 for use in treating or preventing a parasitic infestation in an animal.

18. Use of the compound of formula (Ie) as defined in claim 14 or the compound of formula (S)-Ie as defined in claim 15 in the manufacture of a medicament for treating or preventing a parasitic infestation in an animal.

19. The use of claim 17 or claim 18, wherein the animal is a dog, a cat, an ovine or a bovine.

20. The use of any one of claims 17 to 19, wherein the parasites are fleas and/or ticks.